Streetbeat News

RKDA

Arcadia Biosciences, Inc.

https://www.arcadiabio.com

Industry

Agricultural Inputs

Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.

Open

3.83

Mkt cap

Volume

59K

High

4.14

P/E Ratio

-0.47

52-wk high

5.34

Low

2.80

Div yield

N/A

52-wk low

1.85

Arcadia Biosciences sells its non-GMO Resistant Starch Durum Wheat trait to Corteva Agriscience for $4M, retaining rights for its GoodWheat portfolio use. The deal includes 24 patents in 20 countries, advancing Arcadia's wheat technology monetization.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:08 pm

Arcadia Biosciences (NASDAQ:RKDA) reported Q1 2024 earnings with a GAAP EPS of $(1.78), surpassing the $(2.52) estimate, and sales of $1.255M, exceeding the $1.194M estimate. This represents a significant improvement over the previous year, with an 83.61% increase in EPS and a 1.87% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:56 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Arcadia Biosciences (NASDAQ:RKDA), maintaining a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

April 05, 2024 | 10:20 am

Arcadia Biosciences (NASDAQ:RKDA) reported Q4 earnings with an EPS of $-2.1, beating estimates by 19.0% against an expected $-2.58. Revenue increased by $170 thousand from the same period last year. Despite beating EPS estimates last quarter, RKDA's share price dropped by 3.0% the following day. The company's past earnings performance shows a mixed trend with both beats and misses on EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:30 pm

Arcadia Biosciences reported Q4 earnings with a loss of $2.10 per share, surpassing the expected $2.58 loss, marking a 66.72% improvement from last year. However, their sales of $1.17M fell short of the $1.75M forecast, despite being a 17% increase from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:27 pm

Earnings reports for March 28, 2024, include a mix of expected profits and losses across various sectors. Notable companies like Walgreens Boots Alliance and MSC Industrial Direct Co anticipate earnings, while others like Shimmick and Affimed project losses. The diversity of industries, from healthcare to technology and finance, highlights the varied performance within the market.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:24 am

Arcadia Biosciences (NASDAQ:RKDA) is scheduled to release its quarterly earnings report on March 28, 2024, with analysts expecting an EPS of $-2.58. The company's past earnings performance shows a pattern of beating EPS estimates but experiencing subsequent share price drops. Shares are currently trading at $2.332, reflecting a 71.92% decline over the last 52 weeks. Investors are likely focused on the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 4:00 pm

Arcadia Biosciences has received a Notice of Allowance for its US Patent Application 17/402,216, which focuses on plants with reduced lipase 1 activity for improved shelf-life, stability, rancidity, and flavor of plant products.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 4:23 pm

Arcadia Biosciences, Inc. (NASDAQ:RKDA) has expanded the availability of its high fiber GoodWheat Mac & Cheese, making it available nationwide on Amazon. The product, made from Arcadia's proprietary wheat grain, offers a healthier alternative to traditional mac & cheese with 12g of protein and 8g of fiber per serving. Available in three flavors, it aims to address the widespread fiber deficiency in the American diet. GoodWheat Mac & Cheese is now sold in four-pack varieties on Amazon and at select retailers.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:43 pm

Insiders at Sharps Technology, Better Choice Company, and Arcadia Biosciences have recently made significant stock purchases. These transactions indicate insider confidence in these companies, which are all trading under $3. Sharps Technology's CEO acquired shares following a strategic LOI, Better Choice's Director made a large purchase after a positive earnings report, and Arcadia Biosciences' CFO bought shares also after a favorable earnings outcome.

Portfolio Pulse from Avi Kapoor

February 06, 2024 | 7:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.